Publications
- Nivolumab in treatment of NSCLC2016 | Publication without faculty affiliation
- Immunotherapy of pulmonary carcinoma2015 | Publication without faculty affiliation
- Immunotherapy in lung cancer2014 | Publication without faculty affiliation
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?2022 | Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment2021 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
Loading network view...